Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
US11400108B2 · kind B2 · utility
1Cited by
5References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 7, 2020 |
| Grant date | Aug 2, 2022 |
| Priority date | — |
| Expiry date | Oct 7, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H21/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.